S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501

被引：5

作者：

Fukuda, Minoru ^{[1
]}

Funaki, Soichiro ^{[2
]}

Yamazaki, Takuya ^{[3
]}

Sato, Shuntaro ^{[4
]}

Mukae, Hiroshi ^{[5
]}

Takenoyama, Mitsuhiro ^{[6
]}

Fukuoka, Junya ^{[7
]}

Nabeshima, Kazuki ^{[8
]}

Tateyama, Hisashi ^{[9
]}

Ashizawa, Kazuto ^{[10
]}

Hara, Masaki ^{[11
]}

Seto, Takashi ^{[6
]}

Okumura, Meinoshin ^{[12
,13
]}

Sugio, Kenji ^{[14
,15
]}

机构：

[1] Nagasaki Univ Hosp, Clin Oncol Ctr, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[2] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Osaka, Japan

[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Radiol, Nagasaki, Japan

[4] Nagasaki Univ Hosp, Clin Res Ctr, Nagasaki, Japan

[5] Nagasaki Univ, Grad Sch Biomed Sci, Dept Resp Med, Nagasaki, Japan

[6] Natl Hosp Org Kyusyu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan

[7] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki, Japan

[8] Fukuoka Univ, Dept Pathol, Fac Med, Fukuoka, Japan

[9] Kasugai Municipal Hosp, Dept Pathol, Kasugai, Aichi, Japan

[10] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oncol, Nagasaki, Japan

[11] Nagoya City West Med Ctr, Dept Radiol, Nagoya, Aichi, Japan

[12] Osaka Toneyama Med Ctr, Osaka, Japan

[13] JART, Osaka, Japan

[14] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Oita, Japan

[15] LOGiK, Fukuoka, Japan

来源：

THORACIC CANCER | 2020年 / 11卷 / 03期

关键词：

Cisplatin; radiotherapy; S-1; thymic carcinoma; PHASE-II; CHEMOTHERAPY; CANCER;

D O I：

10.1111/1759-7714.13319

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S-1 treatment is effective against thymic carcinoma. S-1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non-small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression-free survival, and safety.

引用

页码：693 / 696

页数：4

共 50 条

[31] A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
M Ikeda
T Okusaka
Y Ito
H Ueno
C Morizane
J Furuse
H Ishii
M Kawashima
Y Kagami
H Ikeda
British Journal of Cancer, 2007, 96 : 1650 - 1655
[32] Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma
Ajani, JA
Faust, J
Ikeda, K
Yao, JC
Anbe, H
Carr, KL
Houghton, M
Urrea, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6957 - 6965
[33] Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
F Ohyanagi
N Yamamoto
A Horiike
H Harada
T Kozuka
H Murakami
K Gomi
T Takahashi
M Morota
T Nishimura
M Endo
Y Nakamura
A Tsuya
T Horai
M Nishio
British Journal of Cancer, 2009, 101 : 225 - 231
[34] Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
Ohyanagi, F.
Yamamoto, N.
Horiike, A.
Harada, H.
Kozuka, T.
Murakami, H.
Gomi, K.
Takahashi, T.
Morota, M.
Nishimura, T.
Endo, M.
Nakamura, Y.
Tsuya, A.
Horai, T.
Nishio, M.
BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 225 - 231
[35] Neoadjuvant chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Chung, Jooseop
Cho, Goon Jae
Shin, Ho Jin
Choi, Young Jin
Wang, Soo Geun
Lee, Won Sik
Joo, Young Don
Sohn, Chang Hak
Park, Kyung Tae
ANNALS OF ONCOLOGY, 2006, 17 : 182 - 182
[36] PHASE II STUDY OF ORAL S-1 AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
Sudo, Kentaro
Yamaguchi, Taketo
Ishihara, Takeshi
Nakamura, Kazuyoshi
Hara, Taro
Denda, Tadamichi
Tawada, Katsunobu
Imagumbai, Toshiyuki
Araki, Hitoshi
Sakai, Mitsuhirc
Hatano, Kazuo
Kawakami, Hiroyuki
Uno, Takashi
Ito, Hisao
Yokosuka, Osamu
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (01): : 119 - 125
[37] Phase I study of carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced NSCLC
Watanabe, Kageaki
Niho, Seiji
Yoh, Kiyotaka
Goto, Koichi
Hosomi, Yukio
Tanaka, Hiroshi
Okamoto, Hiroaki
Nihei, Keiji
Akimoto, Tetsuo
Ohe, Yuichiro
ANNALS OF ONCOLOGY, 2016, 27
[38] Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer
Sudo, Kentaro
Yamaguchi, Taketo
Ishihara, Takeshi
Nakamura, Kazuyoshi
Shirai, Yoshihiko
Nakagawa, Akihiko
Kawakami, Hiroyuki
Uno, Takashi
Ito, Hisao
Saisho, Hiromitsu
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (01): : 219 - 224
[39] ASO Author Reflections: Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma
Wang, Xintong
Liu, Xiaomeng
Li, Baosheng
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S741 - S742
[40] ASO Author Reflections: Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma
Xintong Wang
Xiaomeng Liu
Baosheng Li
Annals of Surgical Oncology, 2019, 26 : 741 - 742

← 1 2 3 4 5 →